Lilly Alimta patent extended to 2022

Share this article:
Lilly Alimta patent extended to 2022
Lilly Alimta patent extended to 2022

Eli Lilly has added six more years to the patent of its Alimta cancer drug. A lower court decided in favor of the Indianapolis, IN, drugmaker Monday. The decision means the medication, which brought in $2.7 billion in global sales last year and is indicated for nonsquamous non-small cell lung cancer, will not have to face generic competition until 2022.

Bernstein analyst Tim Anderson wrote in his Monday analysis that the win amounts to about three dollars per share, or around 5% of the company's current stock price, but the decision does not change his firm's valuation of Lilly, because its financial models assumed a court would vote in Lilly's favor.

A worst-case scenario could have put Alimta in the generic-eligible bin in 2017. Anderson expects the decision will be appealed, so Monday's news does not mean the patent fights are over.

The company is also fighting for patent extensions in other countries, including Germany and the United Kingdom.

Alimta's US sales totaled $1.2 billion last year, an 8% bump from 2012, due to both higher prices and demand.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...